Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-75 vs ALBENDAZOLE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).
Cystic hydatid disease (Echinococcus granulosus),Neurocysticercosis (Taenia solium),Giardiasis (off-label),Cutaneous larva migrans (off-label),Trichuriasis (off-label),Ascariasis (off-label),Hookworm infections (off-label)
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Primarily metabolized via CYP3A4 in the liver and intestinal mucosa to norfentanyl and other minor metabolites; undergoes extensive first-pass metabolism.
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Reduce dose by 50% and monitor.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <15 m L/min), use with caution; consider dose reduction or extended intervals. No specific GFR-based guidelines available.
Risk of respiratory depression that may result in death; ensure proper patient selection, dosing, and monitoring. Avoid use in opioid non-tolerant patients. Accidental exposure can be fatal. Concomitant use with CNS depressants increases risk. Risk of abuse, misuse, addiction, and diversion. Neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of life-threatening respiratory depression from CYP3A4 inhibitors or discontinuation of CYP3A4 inducers.
Fetal risk cannot be ruled out. In first trimester, no clear evidence of major malformations from opioid analgesics, but data limited. Second and third trimesters: chronic use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS) postpartum. Use during labor may cause respiratory depression in neonate. Risk of preterm birth and low birth weight with prolonged use.
FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal harm; avoid use unless benefit outweighs risk.
DURAGESIC-75 delivers fentanyl at 75 mcg/hour transdermally. Do not use in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-hairy skin on upper torso or upper arm. Avoid heat sources (heating pads, hot tubs) as heat increases absorption. Onset ~12-24 hours; peak effect ~24-72 hours. Remove old patch before applying new; rotate sites. Do not cut or damage the patch. Monitor for serotonin syndrome if used with serotonergic drugs. For breakthrough pain, use immediate-release opioids not additional fentanyl patches.
Albendazole is a broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. It is highly effective against Echinococcus granulosus cysts but requires prolonged therapy (e.g., 28-day cycles). Monitor liver function tests (LFTs) at baseline and every 2 weeks due to risk of hepatotoxicity. For neurocysticercosis, co-administer corticosteroids to reduce inflammatory reaction from cyst degeneration. Albendazole is pregnancy category C; avoid in first trimester and in women planning pregnancy within 1 month of therapy. Absorption is enhanced by a fatty meal; administer with a high-fat meal to increase bioavailability up to 5-fold.
No interactions on record
"The metabolism of Azithromycin can be decreased when combined with Albendazole."
"The metabolism of Theophylline can be decreased when combined with Albendazole."
"The metabolism of Caffeine can be decreased when combined with Albendazole."
DURAGESIC-75 and ALBENDAZOLE are distinct pharmacological agents. DURAGESIC-75 belongs to the Opioid Analgesic class and is primarily used for Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA-approved for opioid-tolerant patients only).. ALBENDAZOLE belongs to the Anthelmintic class and is primarily used for Cystic hydatid disease (Echinococcus granulosus)Neurocysticercosis (Taenia solium)Giardiasis (off-label)Cutaneous larva migrans (off-label)Trichuriasis (off-label)Ascariasis (off-label)Hookworm infections (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURAGESIC-75 carries a safety status of Category C, whereas ALBENDAZOLE safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via microsomal enzymes; undergoes oxidation to albendazole sulfoxide (active metabolite) by CYP3A4 and flavin-containing monooxygenases (FMO). Further metabolized to albendazole sulfone (inactive) and other oxidative metabolites.
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
90-95% bound to alpha-1-acid glycoprotein and albumin
70% bound to plasma proteins, primarily albumin.
6-7 L/kg, indicating extensive tissue distribution
0.2–0.6 L/kg, indicating distribution into tissues; concentrates in liver, bile, and cerebrospinal fluid.
Fentanyl transdermal: 50-65% of patch content absorbed into systemic circulation
Oral bioavailability is low (~5%) due to extensive first-pass metabolism; co-administration with a high-fat meal increases bioavailability up to 4–5-fold.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50%. Class C: Avoid use.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function. No specific dose adjustment guidelines available.
Children ≥2 years: 12.5-25 mcg/hr initial, titrate based on need; max dose 25 mcg/hr for opioid-naive.
For children >2 years: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for most indications. For neurocysticercosis: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 8-30 days. For hydatid disease: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 28-day cycles with 14-day drug-free intervals. For children <2 years: safety and efficacy not established.
Initial dose reduction of 25-50%; titrate cautiously; avoid in frail elderly.
No specific dose adjustment recommended; use with caution due to potential age-related hepatic or renal impairment. Monitor liver function and blood counts regularly.
Albendazole may cause fetal harm when administered to pregnant women. It is contraindicated in pregnancy and should not be used in women who are or may become pregnant. Women of childbearing potential should have a negative pregnancy test before starting treatment and should use effective contraception during therapy and for one month after completion.
No significant food interactions. Grapefruit juice may increase fentanyl levels via CYP3A4 inhibition; caution with high intake. Avoid alcohol due to additive CNS depression.
Take with a high-fat meal (≥40 g fat) to significantly increase oral bioavailability. Avoid grapefruit juice as it may affect drug metabolism. No specific dietary restrictions otherwise.
Fentanyl is excreted in breast milk. M/P ratio approximately 0.4. Breastfeeding is generally not recommended during Duragesic-75 use due to risk of infant sedation and respiratory depression. If used, monitor infant for unusual sleepiness, difficulty breathing, or poor feeding. Alternative analgesics are preferred.
Excreted in breast milk; M/P ratio not established. Use with caution, especially in neonates due to risk of bone marrow suppression.
No specific dose adjustments are established for Duragesic-75 in pregnancy. Fentanyl pharmacokinetics may be altered due to increased plasma volume, renal clearance, and hepatic metabolism; however, transdermal absorption may be inconsistent. Use lowest effective dose for shortest duration. Consider alternative opioids with more pregnancy data. Taper dose before delivery to reduce NAS risk.
No specific dose adjustment recommended in pregnancy; pharmacokinetic changes not well studied. Use lowest effective dose and shortest duration possible.
Apply the patch to a flat, non-hairy area of the upper body or arm. Do not use on skin that is irritated, cut, or scarred.,Do not expose the patch to direct heat sources like heating pads, electric blankets, hot tubs, or sunbathing—this can cause a dangerous overdose.,Wash hands after handling the patch. Dispose of used patches by folding sticky sides together and flushing down toilet per FDA guidelines.,Remove the old patch and apply the new patch to a different skin site every 72 hours (3 days). Rotate sites to avoid skin irritation.,Do not cut, chew, or damage the patch—this can lead to rapid release of fentanyl and fatal overdose.,Store patches in a secure place away from children and pets. Accidental exposure can be fatal.,Common side effects include nausea, vomiting, constipation, dizziness, and drowsiness. Report severe drowsiness, confusion, difficulty breathing, or signs of an allergic reaction.,Avoid alcohol, other opioids, benzodiazepines, and sedatives as they increase risk of respiratory depression.,Do not stop using this medication suddenly; taper with prescriber to avoid withdrawal symptoms.,Seek emergency care for symptoms of overdose: slow or shallow breathing, extreme drowsiness, or unresponsiveness.
Take this medication with a fatty meal (e.g., eggs, avocado, nuts) to improve absorption.,Do not crush or chew the tablets; swallow them whole with water.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea, or abdominal pain.,Avoid pregnancy during treatment and for at least 1 month after the last dose; use reliable contraception.,You may experience dizziness or blurred vision; avoid driving or operating machinery until you know how the drug affects you.,If you are breastfeeding, discuss with your doctor before taking this medication.